Compound class:
Synthetic organic
Comment: We obtained the chemical structure for crozbaciclib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a cyclin-dependent kinase inhibitor and antineoplastic. This Chemical structure mapped to PubChem CID 129202507 which has the synonym 'CDK4/6/1 Inhibitor, and via ChEMBL to compound 11 in Yin et al. (2018) [1]. Compound 11 was optimised to cross the blood-brain barrier, and is intended as a therapy for glioblastoma multiforme.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H. (2018)
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem, 144: 1-28. [PMID:29247857] |